Sprintronics

Project TitleSprintronics
Year Start2012
Year End2014
Consortium members 
Description
Core TechnologyConductive Nanomaterials
Industry of applicationConductive materials
CallConecta Peme
Funding info

NANOPLATA

Project TitleNANOPLATA
Year Start2008
Year End2009
Consortium membersTECNALIA (CIDEMCO)
NANOGAP
XYLAZEL
DescriptionStudy of metallic silver nanoparticles (Ag) as future active ingredients in wood preservative products.
Synthesis of metal NPs of Ag of different sizes.
Adequate functionalization of the NPs in order to achieve a homogeneous dispersion and its “anchoring” in the final formulations for the preservation of wood.
Study of the scaling of the optimal products at an industrial level.
To determine the biological effectiveness of the metallic NPs of Ag against the different xylophagous organisms and to be able to assess the scope of application (classes of use) of the future ones formulated in the sector of the protection of the wood.
Core TechnologyAtomic Quantum Clusters
Industry of applicationAM
CallMinisterio de Industria
Funding infoProject financed by the FEDER Funds (European Regional Development Fund) through the Ministry of Science and Innovation of the Government of Spain

Nano Natural Stone

Project TitleNano Natural Stone
Year Start2012
Year End2014
Consortium membersGAIRESA
GRUPO CUPA
NANOGAP
DescriptionThe objective of Nano Natural Stone is to carry out an industrial research project that allows obtaining a validation of generic technology capable of incorporating nanotechnological applications novelties on Galician natural stones for various applications, among which includes the improvement of the thermal conductivity of stones and photocatalytic treatments. The stones of greatest importance and tradition in the Galician industry: granite and slate. On these, are intended to apply coatings able to adhere to the stone. These coatings will be loaded with nanoparticles that provide new properties to stone supports. To allow adhesion of coatings loaded with nanoparticles to the stones, are carried out on these superficial treatments of honing and superficial and volumetric treatments using laser technologies. It is therefore intended to investigate new methods to incorporate cutting-edge technology, as it is nanotechnology and laser treatments, to a traditional material such as natural stone that improve its intrinsic properties. For this, an investigation of nanomaterials will be carried out, coatings and treatments of natural stone. The research in nanomaterials will deepen the methodology of preparation of nanomaterials and in the optimization of their morphology. It is looking to get more manufacturing efficient and controlled nanomaterials, specifically nanofibers and Quantum Clusters Atomic (ACQs). In addition, a validation methodology will be developed to verify the validity of the nanomaterials obtained from the developed techniques.
Core TechnologyAtomic Quantum Clusters, Conductive Nanomaterials
Industry of applicationAQCSs+Cond
CallInterconnecta
Funding infoThe project Nano Natural Stone has received funding from the FEDER Innterconecta funds, managed by CDTI

Degrade

Project TitleDegrade
Year Start2018
Year End2020
Consortium membersINTACTA ENVIRONMENTAL MANAGEMENT S.L
NANOGAP SUB-MN-POWER S.A
LEDISSON LIGHTING S.L
CETIM Technological Center
DescriptionDEGRADE project aims to design and develop a system that allows the adaptation of the current channel disinfection systems by UV radiation of the wastewater treatment plants, to achieve not only a disinfection treatment but also the elimination of the emerging contaminants present (mainly Carbamazepine, Diclofenac, 17-β-estradiol and Bisphenol A, and Propylparaben). For this purpose, a technology based on photoelectrocatalysis will be developed, through the combination of UV-LEDs, which replace the current LED lamps, with photocatalysts based on noble metal nanoclusters supported on a conductive material, and the generation of sulfate radicals, highly oxidants, in order to achieve target mineralization and elimination rates of both emerging organic pollutants and pathogens.
Core TechnologyNano Catalysts
Industry of applicationCatalysis
CallConecta Peme
Funding infoThe project has been funded by the Galician Innovation Agency within the framework of the 2018 call of the CONECTA PEME Program. It has been supported by the Ministry of Economy, Employment and Industry (Xunta de Galicia) and co-financed by the European Regional Development Fund (ERDF) within the framework of the Operational Program FEDER Galicia 2014-2020, Thematic Objective 1: “Promote development technology, innovation and quality research. “.
Progress 2018:
Characterization of the wastewater of two WWTPs has begun with different characteristics, in order to determine the concentrations of microorganisms and emerging pollutants, as well as usual physical-chemical parameters. In addition, the identification of the essential parameters for DEGRADE technology as the wavelength of the LEDs, nanocluster type, etc.
On the other hand, a comprehensive study of current and future legislation on concentration has been carried out maximum allowed for organic pollutants in wastewater both nationally and international.
Finally, the determination of the main technical parameters for the development of nanoclusters, as well as the beginning of the design and approach to their synthesis through the Evaluation of the different methodologies.
2019:
Characterization of the wastewater has been completed, which has allowed to establish the base concentration of emerging and microbiological contaminants, as well as finalize the identification of the essential parameters for the development of DEGRADE technology.
On the other hand, the work of synthesis of nanoclusters and the study of their activity have been carried out
Photocatalytic
In addition, the deposition of the nanoclusters on a conductive material has been carried out and have initiated the tests o photoelectrocatalytic activity.
Finally, work has begun on the optimization of laboratory-scale parameters for degradation of emerging contaminants and disinfection, as well as the design work of the pilot pilot plant.
Logotipo Conecta Peme GAIN

LEMBDA

Project Title Lembda
Year Start 2014
Year End 2015
Consortium members NANOGAP
GalChimia
Softgasa
AMSLab
Description Light emitting nanomolecules for biomedical diagnostics applications (LENBDA) project  is aimed to study the industrial use of a biomolecules detection system based on highly specific luminiscent nanoemitters. The system offers a complete solution for the detection of biomolecules in a specific, interference-free way. To accomplish this goal, a fully functional prototype of the diagnostic kit will be developed to be used in pathology labs , so no additional equipment will be needed. In the final stage, the project will be validated against tumor cell lines available in tissues banks.
Core Technology Atomic Quantum Clusters
Industry of application Healthcare & Therapeutics
Call Conecta Peme
Funding info LEMBDA project has been financed with a grant of 161.692,38€ by the Xunta of Galicia and the European Union FEDER (Operative Program FEDER GALICIA 2007-2013) through the subprogramme CONECTA PEME.

Neogalfarm

Project Title Neogalfarm
Year Start 2016
Year End 2018
Consortium members Galchimia
AMSLAB
Oncostellae plus several research groups from the University of Santiago de Compostela (USC)
The Health Research Institute of Santiago de Compostela (IDIS)
LEITAT
Description Nuevos fármacos contra el cáncer: Desarrollo de terapias dirigidas a dirferentes dianas terapéuticas y de tratamientos combinados (NEOGALFARM) aim is to find new treatments for cancer with the development of therapies aimed at different therapeutic targets and combined treatments. 
Core Technology Atomic Quantum Clusters
Industry of application Healthcare & Therapeutics
Call Conecta Peme
Funding info This Project was granted by the Agencia Gallega de Innovación (GAIN) through the Conecta Peme Program, co-financied by European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Emprego e Industria (Xunta de Galicia). The total budget was fixed at 1,076,339.63 euros.
ObjectivesSearch for new drugs for cancer treatment through the development of therapies aimed at different therapeutic targets and combined treatments:
Develop new androgen receptor antagonists that are effective in animal models of prostate cancer and nominate a preclinical candidate.
To develop new modulators of protein-protein interactions of the Bcl-2 family that are effective in animal models of cancer.
Discover new inhibitors of the ALK5 kinase (Activin receptor-Like Kinase) and the TGF-beta signaling pathway that are effective in animal models of cancer.
Discover new inhibitors of JAK kinase (Janus Kinase) that are effective in animal models of myeloproliferative, hematological or solid tumor diseases.
Development of new types of nanomaterials that have anti-tumor activity with low toxicity and / or that enhance the action of anti-tumor drugs directed against DNA.
Study the synergy of these different mechanisms of action to treat various types of cancers in vitro and in vivo.
Develop highly selective and sensitive analysis methods based on mass spectrometry coupled to liquid chromatography, which allow to measure the concentrations of chemical compounds developed and their metabolites in both plasma and tumors. In addition, biomarkers will be identified applying proteomics techniques and tools based on high resolution mass spectrometry.
ResultsPotent and patentable inhibitors of ALK5 have been identified. The pharmacokinetic properties of the best inhibitors identified in ALK5 have been characterized.
A series of GI-restricted inhibitors of JAK3 / TYK2 has been developed and patented for the IBD-fibrosis-colon cancer axis, which are active in the murine model of colitis and do not present high-dose toxicity. These products are about to start the first clinical study at Hospital Sant Pau in Barcelona.
A series of systemic JAK3 / TYK2 inhibitors for psoriasis has been developed and patented. These products are powerful and selective, and their properties make them especially interesting for oral and topical treatment.
A series of AR + GR antagonists for prostate cancer has been developed and patented that could potentiate the current treatments with enzalutamide.
Non-steroidal GR antagonists have been identified as activators of the immune system with potential for the treatment of colon cancer.
A potential synergy of the ALK5 inhibitors discovered by GalChimia with JAK antagonists discovered by Oncostellae has been identified.
An effective method for the synthesis of AQCs of different sizes has been successfully developed.
It has been found that smaller AQCs increase the accessibility of chromatin in proliferating cells, enhancing the effect of drugs whose target is DNA, so they could improve the effectiveness of current treatments.
It has been proven that the larger AQCs have the ability to cross the blood brain barrier to reach and reduce metastases, constituting an innovative tool to solve two of the main problems in the treatment of cancer.
Highly selective and sensitive analysis methods based on HPLC-MS have been developed to measure the concentrations of chemical compounds developed and their metabolites, both in plasma and in tumor.
Biomarkers have been identified applying proteomics techniques and tools based on high resolution mass spectrometry